Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference
(Thomson Reuters ONE) -
Medigene AG /
Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH
conference
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 20 November, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces that early clinical data of its Dendritic Cell (DC) vaccines
will be presented at the upcoming 56(th) American Society of Hematology (ASH)
Annual Meeting taking place from December 6 - 9 2014 in San Francisco, USA. The
clinical data to be presented were collected in a compassionate use program,
conducted at the Department of Cellular Therapy at the Oslo University Hospital,
Norway, under the responsibility of Prof. Gunnar Kvalheim and Iris Bigalke. The
poster presentation titled "Vaccination with a New Generation of Fast Dendritic
Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount
Strong Immune Responses and Prolong Survival." shows data from patients with
various types of tumour which were included in this program.
The Oslo University Hospital has an agreement with Medigene for use of
Medigene`s new generation DC vaccines for their ongoing academic clinical
studies.
To view the abstract of the presentation please visit:
https://ash.confex.com/ash/2014/webprogram/Paper74148.html
Furthermore, Medigene informs that an abstract on an investigator initiated
phase II clinical trial with Medigene's DC vaccines for the treatment of
prostate cancer currently being conducted by the Oslo University Hospital can be
found at:
http://www.eacr.org/pivac14/downloads/PIVAC14%20online%20prog%20book.pdf
(p. 17 of the abstract book).
About Medigene's DC vaccines: The platform for the development of antigen-
tailored DC vaccines is the most advanced platform of the three highly
innovative and complementary immunotherapy platforms of Medigene Immunotherapies
(formerly Trianta Immunotherapies), which was recently acquired by Medigene AG.
Currently the DC vaccines are being evaluated in two ongoing investigator-
initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute
myeloid leukaemia). Medigene concentrates on the further development of DC
vaccines in hematological malignancies and plans to initiate a further clinical
study in AML in 2014.
Medigene's dendritic cell product platform allows the design of new generation
dendritic cell vaccines. Dendritic cells can take up antigens efficiently,
process them and present them on their surface in a form that can activate
antigen-specifc T cells to divide and mature and thus enable the T cells to
attack tumour cells. Dendritic cells can also induce natural killer cells to
become active and attack tumour cells. Medigene Immunotherapies has established
new, fast and efficient methods for preparation of autologous (patient-specific)
mature dendritic cells that have relevant characteristics to activate both T
cells and natural killer cells. They are developed to carry multiple tumour
antigens and can be tailored to treat various types of cancer, suited for
treatment of minimal residual disease or use in combination therapies.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) is a registered trademark of Medigene AG. Medigene
Immunotherapies(TM) is a registered trademark of Medigene Immunotherapies GmbH.
Trianta Immunotherapies(TM) is a registered trademark of Medigene
Immunotherapies GmbH. These trademarks may be owned or licensed in select
locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1872836/659411.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1872836]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="SecureCom Mobile Inc. Appoints Ralph Scobie as CEO and DirectorDatum: 20.11.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 354146
Anzahl Zeichen: 6103
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 212 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
